Diagnosis and classification of poorly differentiated tumors with primitive features of the central nervous system heavily relies on molecular and genetic findings of the tumors. Although RB1 gene mutation underlies the development of retinoblastoma and many other systemic cancers, RB1 gene mutation in a brain tumor is mainly limited to infiltrating gliomas. We describe what we believe to be a hitherto unreported case of sellar/suprasellar embryonal tumor with distinctive Flexner-Wintersteiner rosette formation, and somatic RB1 gene mutation in a 5-month-old infant. There were no molecular features associated with the embryonal tumor with multilayered rosettes, and there were no histological or genetic features of a germ cell tumor. A follow up of 14 months duration showed good clinical response to VETOPEC regimen and no development of retinal disease. Our case shows an interesting association between RB1 mutation and Flexner-Wintersteiner rosettes in an embryonal tumor of the central nervous system and underscores the utility of large scale next generation sequencing in helping to identify the genetic aberrations that may help in clinical pathologic correlations of unusual or out-of-place histologic findings.
INTRODUCTION
Traditionally, a number of tumors variably fell under the umbrella term, central nervous system (CNS) primitive neuroectodermal tumor (PNET), including the well-defined entities such as medulloblastoma, pineoblastoma and atypical teratoid rhabdoid tumor, as well as the less well-defined category of supratentorial PNETs, such as CNS neuroblastoma, "ependymoblastoma," and "medulloepithelioma." With incorporation of molecular data, the waste-basket term, PNET, has fallen out of favor and has been replaced in the 2016 update of the WHO classification of the CNS tumors with CNS embryonal tumor; many of the previous CNS PNETs have been found to have common mutations and are now considered "embryonal tumors with multi-layered rosettes (ETMRs)" (1) . Those cases without distinctive histologic or molecular alterations are now labeled as "embryonal tumor, not otherwise specified (NOS)" (2) . Some CNS embryonal tumors are associated with familial syndromes and distinctive germline mutations, e.g. rhabdoid tumor predisposition syndrome 1 and 2 involving SMARCB1 and SMARCA4 gene, respectively, pineoblastoma in familial retinoblastoma, and DICER1 germline mutation, etc. (3, 4) . Interestingly, in patients with germline RB1 mutation, they have a slight tendency of developing a second focus of intracranial embryonal tumor typically located in the pineal gland or supra/parasellar region, a few years after the diagnosis of bilateral retinoblastoma, a condition called "trilateral retinoblastoma" (5, 6) . Hereby, we describe a unique case of a sellar/suprasellar embryonal tumor with prominent Flexner-Wintersteiner (FW) rosette formation, closely resembling a retinoblastoma morphologically, in a 5-month-old infant. A somatic RB1 gene mutation was identified in the tumor. The patient responded well to VETOPEC (vincristine, etoposide, and escalating cyclophosphamide) based protocol and there has been no development of other disease, including retinal disease, in follow up of 14 months duration.
Clinical Summary
The patient was a 5-month-old Asian girl with an unremarkable antenatal history, who presented with poor feeding, vomiting and sunset eyes of 1-month duration. No signs or symptoms of endocrine insufficiency or overproductions were observed. There was no family history of malignancy, in particular retinoblastoma. Physical examination showed a head circumference which corresponded to 90th percentile of her age. There was medial deviation of the left eye, generalized hyperreflexia and hypertonia with rigid back. A ventriculoperitoneal shunt was previously inserted at another hospital.
Serum beta-human chorionic gonadotropin was <2 IU/L and alpha-fetoprotein was 80 ng/mL (reference range for age of 160 days: 1.25-130 ng/mL). Lactate dehydrogenase (LDH) level, which is a nonspecific tumor marker, was markedly elevated, up to 2110 U/L (reference range: 320-860 U/L), indicating an underlying neoplasm with rapid cell turnover rate and large tumor burden. Computed tomography and magnetic resonance imaging (MRI) of the brain and spine showed a large, heterogeneously enhancing, hemorrhagic mass centered at the sellar/suprasellar region measuring 4 Â 3.8 Â 3.6 cm, associated with extensive leptomeningeal dissemination, predominantly extending into the basal cisterns and Sylvian fissures, as well as extending inferiorly to the foramen magnum and spinal cord (Figs. 1A, B, 2A ). There was also extension into the third and fourth ventricles and cerebral aqueduct, associated with dilation of the lateral and third ventricles. Adjacent mass effect was seen with compression of the bilateral frontal lobes, midbrain, pons, cerebellum, optic chiasm, and the proximal prechiasmatic bilateral optic nerves. The pineal gland tumor was difficult to identify and appeared to be contiguous with the extensive leptomeningeal tumor deposit in the posterior fossa. The visualized nasal cavity, paranasal sinuses and mastoid cells were clear. The brainstem and spinal cord involvement are likely accountable for the nonconjugate visual symptoms and signs of upper motor neuron involvement, respectively, on physical examination. A biopsy of the suprasellar mass was performed. No biopsy of the pineal mass was done. Following the histopathological diagnosis, fundoscopic examination and MRI imaging were performed and revealed no evidence of retinal disease. Whole body imaging was however not done in view of lack of clinical findings of extracranial/spinal diseases. The patient received neoadjuvant chemotherapy following the VETOPEC-based regimen for solid tumors (7). After 1 cycle of chemotherapy, LDH level dropped to within normal range, which was 850 U/L, indicating a good treatment response. A repeat MRI brain and spine after 2 cycles of chemotherapy showed a relatively stable sellar/suprasellar mass, whereas the diffuse leptomeningeal deposits in the posterior fossa and spine showed significant improvement. Four more cycles of chemotherapy were given and, thereafter, the patient underwent resection of the suprasellar mass. Postoperatively, the patient remained neurologically stable but developed panhypopituitarism. Because of her age, radiation was not given. She continued on oral metronomic chemotherapy (8) . MRI brain and spine performed postoperatively as well as 3 months after completion of intravenous chemotherapy, while on oral metronomic chemotherapy, showed a significant reduction in size of the sellar/ suprasellar mass, resolution of the enhancement in the posterior fossa, as well as near complete resolution of the spinal leptomeningeal enhancement. The latest imaging which was performed 12 months after the diagnosis showed a postoperative tumor cavity with no residual enhancement in the sellar/suprasellar region as well as resolution of the leptomeningeal enhancement of the posterior fossa and spine (Figs. 1C, D, 2B ). Patient remains well at 14 months of follow up since diagnosis.
MATERIALS AND METHODS
Both the first biopsy specimen and the second postneoadjuvant chemotherapy resection specimen were entirely submitted and routinely processed for paraffin embedding and staining with hematoxylin and eosin (H&E). Sections from the first biopsy specimen were immunostained for the tissue antigens with commercially available primary antibodies, including synaptophysin (DAKO, Glostrup, Denmark), neurofilament protein (DAKO), NeuN (Millipore, Temecula, CA), GFAP (DAKO), EMA (DAKO), CAM5.2 (Ventana, Tucson, AZ), H3K27M (Millipore), LIN28A (Cell Signaling Technology, Danvers, MA), CD99 (DAKO), OCT4 (Cell Marque, Rocklin, CA), SALL4 (Roche, Tucson, AZ), INI1 (Becton Dickinson, Franklin Lakes, NJ), and BRG1 (Abcam, Cambridge, MA), following the locally validated dilutions and tissue preparations. The biopsy specimen was also sent to Foundation One for genomic alteration analysis via next generation sequencing (NGS) based assay (9) . In addition, the peripheral blood of the patient was also sent for RB gene mutation analysis to look for underlying germline mutation using TruSight DNA sequencing (Illumina, San Diego, CA). Briefly, targeted NGS was performed on 50 ng of purified genomic DNA isolated from patient's blood to detect germline variants in 94 cancer-predisposition genes using the TruSight Rapid Capture Kit and TruSight Cancer Sequencing Panel. MiSeq sequencing data were processed using the MiSeq Reporter software version 2.2.31.1 with Enrichment application. Variant call format files were annotated with Variant Studio Software v3.0. Additionally, exons 8 and 18 of the patient's RB1 gene were subsequently sequenced by bidirectional Sanger sequencing (Applied Biosystems, Austin, TX) to verify the NGS findings.
Electron microscopy was not performed.
RESULTS
H&E-stained histological sections of the first biopsy specimen showed fragments of tumor tissue composed entirely of primitive, embryonal cells with high nucleo: cytoplasmic ratio and blastic chromatin pattern, associated with abundant, well-formed FW rosettes and some Homer Wright (HW) rosettes (Fig. 3A, B ). Brisk mitotic activity was seen, as well as scattered apoptotic bodies. Scattered zones of dystrophic calcification were also present. No neuropil-rich zones, fleurettes, rhabdoid features, ganglion cells, multi-layered rosettes, pigments, teratomatous, or germ cell components were identified. On immunohistochemical examination, the tumor cells showed diffuse cytoplasmic positivity for synaptophysin (Fig. 3C) . No background synaptophysin-positive neuropil was identified. No expression for LIN28A, neurofilament, NeuN, GFAP, EMA, CAM5.2, H3K27M, CD99, OCT4, or SALL4 was seen. INI1 and BRG1 were intact. A diagnosis of embryonal tumor, NOS, WHO grade IV was rendered with comments that the morphological features and immunoprofile were those of an embryonal tumor with retinoblastic/neuroblastic differentiation. The negativity for LIN28A, H3K27M, OCT4, and SALL4 as well as retained INI1 and BRG1 made ETMR, pediatric-type glioblastoma, germ cell tumor and atypical teratoid rhabdoid tumor less likely. In view of the prominent FW rosettes, other possibilities include metastatic retinoblastoma and pineoblastoma. Close clinical and imaging correlation was recommended. Genomic analysis reported from Foundation One revealed a somatic mutation in the RB1 gene, including 2 nonsense substitutions at codon 575 and 251 (Q575*, R251*). No germline RB1 mutation was identified from the peripheral blood sample of the patient. The subsequent post-neoadjuvant therapy resection specimen showed extensive tumor necrosis and prominent dystrophic calcification, consistent with treatment effect (Fig. 3D) . Focal residual viable tumor was present, showing similar morphological features as described above with numerous FW and HW rosettes. No divergent differentiation was present. 
DISCUSSION
The prominent FW rosette formation was a key finding and highlight of our case. A FW rosette is characterized by tumor cells neighboring a central lumen that contains cytoplasmic extensions from the tumor cells. The lumen corresponds to subretinal space whereas the cells surrounding the lumen are joined near the apices by intracellular connections (zonulae adherentes), akin to the external limiting membrane of the retina. Hence, the FW rosette is recognized as an early attempt for retinal differentiation (10, 11) . FW rosette formation is a characteristic finding in retinoblastoma, but they are not pathognomonic as they can also be encountered in other embryonal tumors, such as pineoblastoma and the old-termed medulloepitheliomas, ependymoblastoma, or embryonal tumor with abundant neuropil and true rosettes, now also known as ETMR (10, (12) (13) (14) . On the other hand, the HW rosette is typically seen in neuroblastoma, medulloblastoma, PNET, and retinoblastoma. They lack a central lumen and their constituent cells encompass a central tangle of neural filaments. Their presence indicates neuroblastic differentiation (11) .
The RB1 gene is a negative cell cycle regulator, maintaining a balance between cell proliferation and development (15) . Mutations in RB1 underlie the development of retinoblastoma, a rare tumor that arises at a rate of $1:20 000 live births, with nearly 5000 new cases worldwide per year (16) . Nevertheless, mutations in RB1 gene can also be found in other brain tumors, mainly in the infiltrating gliomas (17) (18) (19) (20) (21) . Interestingly, a small percentage of patients with germline RB1 mutation and bilateral retinoblastomas can develop a second focus of intracranial embryonal tumor, a condition known as "trilateral retinoblastoma" (5) . This second focus of disease usually appears a few years after the retinal tumors, when the child has had no evidence of active retinoblastoma in the eyes or elsewhere (22) . Classically, the second intracranial focus develops in the pineal region or supra/parasellar region, and rarely in the third ventricular region (6, 23 ). An extensive literature search was done in the English neuropathologic literature and we found only a single case that showed slight similarity to our case. In a case series by Kingston et al, they reported a child who presented with an isolated suprasellar tumor but no evidence of retinal disease (24) . However, this patient had a positive family history of retinoblastoma (mother and a younger sister with bilateral retinoblastoma), indicating the likelihood of underlying RB1 germline mutation in this patient. The disease progressed rapidly and the patient died 4 months after the diagnosis. While most retinal disease develops prior to the diagnosis of the second focus of intracranial disease in cases of trilateral retinoblastoma, Bader et al documented 3 patients who presented with a retinoblastoma-like tumor of the suprasellar or parasellar region 2-6 months prior to the diagnosis of retinoblastoma (22) . Two patients had bilateral eye tumors, but none had a positive family history of retinoblastoma. The third patient had a very small retinal tumor in 1 eye.
The peculiar tendency of intracranial disease to develop in the pineal and supra/parasellar region in cases of trilateral retinoblastoma has led to the concept that the RB gene confers increased susceptibility to a narrow spectrum of neuroblastic tumors that usually present in the retina but which can also occur ectopically, particularly in cells of photoreceptor origin (22) . It is well known that pineal gland shows photoreceptor function and retina-like morphology, leading to its designation as a "third eye" (25) . The possible existence of ectopic retinal cells in the suprasellar region has been discussed by Jakobiec et al (26) . The ectopic retinal cells may be present along the developmental pathway as embryological remnants since the optic cup develops as an outpouching of the future diencephalon. Indeed, ectopic rests of retinal cells have been found along the optic tract and in the hypothalamic region of patients with various severe ocular anomalies, such as synophthalmia and the specific chorioretinopathy of Aicardi's syndrome (26) (27) (28) . Bullitt and Crain proposed that ectopic retinoblastoma may arise in the diencephalon, including the floor of the third ventricle from germinal matrix cells near those that normally give rise to the optic cup in genetically predisposed patients (29) . This hypothesis is supported by rare reports of intracranial retinoblastoma involving the third ventricle (6, 23) . We hypothesize that our tumor represents a cerebral neuroblastoma with retinoblastic differentiation, arising in the genetic landscape of a somatic RB1 mutation in the sellar/suprasellar region; in the absence of a germline RB1 mutation, no retinal disease occurred. In addition, the involvement of both sellar/suprasellar and pineal gland may suggest a multicentric origin, a phenomenon akin to the inherited form of retinoblastoma in which independent tumor foci may develop in each eye (30) . The hypothesis is further supported by the fact that metastasis to the pineal gland is an extremely rare event.
It has been debatable that the second focus of intracranial disease in trilateral retinoblastoma merely represents a metastatic spread from the eyes. In most such cases there is absence of pathological features usually associated with the development of metastases from the retinal tumors, namely, invasion of the optic nerve posterior to the lamina cribrosa, massive choroidal invasion and intraorbital extension (22) . In addition, most of the intracranial disease in trilateral retinoblastoma presented as a solitary discrete mass, in contrast to the typical diffuse leptomeningeal spread or multiple cerebral lesions in metastatic retinoblastoma. There is also a long latent interval from the diagnosis of retinoblastoma to the development of the intracranial disease (22) . The histological features of the index case as well as the sole RB1 mutation raised strong suspicion of this being a metastatic retinoblastoma prompted screening of retinal/extracranial disease in our patient. In the event of it being a metastatic disease, the prognosis would differ significantly and the main treatment would be palliation. Nonetheless, with the advent of chemotherapy, retinoblastoma has evolved from a deadly childhood cancer to a largely curable cancer within the last few decades. The 5-year survival of patients with trilateral retinoblastoma syndrome has significantly increased in the past decade from 6% to 44%, probably due to better chemotherapy regimens and earlier detection of intracranial disease (4) . It is interesting to note that there was no retinal disease or germline RB1 mutation in our patient, although a mosaicism is not completely excluded. It is possible that our patient has had small retinal disease that was not detected clinically and responded to the chemotherapy given. Close clinical follow up of our patient is indicated, particularly regarding future development of retinal disease. The presence of pineal gland involvement and extensive cerebrospinal fluid dissemination in our patient also raised the possibility of it being a metastatic pineoblastoma. Photoreceptor-type differentiation may be seen as FW rosettes or fleurettes in pineoblastoma. Nevertheless, the dominant mass in our patient was in the sellar/suprasellar region, whereas the pineal gland tumor appeared to be a secondary involvement from the extensive leptomeningeal deposits in the posterior fossa. It is also interesting to note the unequal chemo-responsiveness between the sellar/suprasellar mass and the diffuse leptomeningeal deposits in the posterior fossa, noted from the MRI scan performed after 2 cycles of chemotherapy. In addition, pineoblastoma manifests mainly in the first 2 decades of life, with mean patient age of 17.8 years (4). It is noteworthy that specific abnormalities of chromosome 13q in the region of the RB1 gene were not found in conventional or comparative genomic hybridization cytogenetic studies of pineoblastoma (31, 32) .
ETMR is characterized by C19MC alterations (including amplification and fusion) in the C19MC locus at 19q13.42. In fact, any CNS embryonal tumor with C19MC alterations qualifies for this designation, including those without distinctive histological features (1) . Evaluation of C19MC and LIN28A status should be considered for all malignant neuroepithelial tumors arising in young children, regardless of location. On the other hand, "CNS embryonal tumor, NOS" is a term suggested for embryonal tumors that lack specific histological features or molecular alterations that define other CNS tumors (2). Our case is composed entirely of primitive cells that lack LIN28A cytoplasmic expression, supported by an absence of other molecular aberrations apart from the RB1 mutation from the genomic analysis by Foundation One. Therefore, CNS embryonal tumor, NOS is an appropriate diagnosis in this setting.
The other potential differential in the index case is a predominant neuroepithelial component of an undersampled immature teratoma or a predominant somatic malignancy in the form of PNET arising in an undersampled germ cell tumor. This differential is supported by the fact that the majority of CNS germ cell tumors arises along the midline axis extending from the pineal gland to the suprasellar compartment, as well as the tremendous response to chemotherapy in this case. Nevertheless, the infantile age group of the index patient and normal serum germ cell markers render this differential less likely, since primary CNS germ cell tumor usually has a peak incidence around puberty (33) . The imaging findings of a discrete sellar/suprasellar mass and an indistinct pineal gland, which was enmeshed with the rest of posterior fossa tumor, are also atypical for a bifocal germ cell tumor. Although it was only a biopsy and an incomplete resection, both specimens were entirely submitted for histological evaluation and revealed no evidence of a germ cell component. There was also no expression for pan-germ cell markers, such as OCT4 or SALL4 in the tumor cells. Furthermore, the genomic analysis from Foundation One revealed a low mutation burden (2 mutations per megabase) of the tumor cells with absence of the common genetic anomalies found in intracranial germ cell tumors, such as mutations in the KIT/RAS and AKT/mTOR pathways, mutations involving BCORL1, MTOR, TP53, and SPTA1, as well as copy number alterations of CCND2 and RB1 genes (33, 34) . It is also interesting to note that germ cell tumor with somatic malignancy in the form of PNET usually shows a poorer response to chemotherapy and is associated with a poorer overall survival (35) . Although the duration of follow up in our patient is only 14 months to date, the massive treatment response in our case is not in keeping with this observation. The overall findings argue against the possibility of a germ cell tumor.
Given the sellar involvement in a pediatric patient, a recently described embryonal tumor of the neonatal pituitary, "pituitary blastoma" may enter into consideration (36) . Pituitary blastoma mostly arise in infants younger than 24 months of age. The majority of the patients showed signs and symptoms of Cushing syndrome followed by ophthalmoplegia (36) (37) (38) . The overall survival of patients with pituitary blastoma is poor with 40% death in the first 26 months after diagnosis (37, 38) . Histologically, pituitary blastoma exhibits complex morphology, consisted of Rathke-type epithelial glands with rosette-like formations, small primitive appearing cells with blastemal-like appearance and large secretory epithelial cells resembling adenohypophyseal cells, reflecting an arrested pituitary development and unchecked proliferation. The clinical and histological features of pituitary blastoma were not compatible with the index case.
In summary, we present a highly unusual case of an intracerebral embryonal tumor with distinctive retinoblastic differentiation and a somatic RB1 gene mutation in a 5-monthold infant, without underlying germline RB1 mutation nor retinal disease in the 14 months of follow up. The patient responded well to VETOPEC regimen. Our case shows an interesting association between RB1 mutation and FW rosettes in a CNS embryonal tumor and underscores the utility of large scale NGS in helping to identify genetic aberrations that may help in clinical pathologic correlations of unusual or out-ofplace histologic findings.
